Mechanism of action
Risperidone exerts its antipsychotic effects through antagonism of dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also has high affinity for serotonin 5-HT2A receptors, where antagonism may reduce negative symptoms and cognitive deficits while partially offsetting extrapyramidal side effects.
The 5-HT2A/D2 binding ratio is dose-dependent: at lower doses, 5-HT2A blockade predominates, but at higher doses, D2 antagonism becomes more prominent, leading to increased risk of extrapyramidal symptoms (EPS) and hyperprolactinemia. Risperidone also blocks alpha-1 adrenergic receptors (causing orthostatic hypotension), histamine H1 receptors (sedation and weight gain), and has minimal anticholinergic activity compared to first-generation antipsychotics.
The active metabolite 9-hydroxyrisperidone (paliperidone) contributes significantly to therapeutic effect and has a similar receptor binding profile. This metabolite is formed by CYP2D6 and is marketed separately as paliperidone.
- Risperidone causes the highest hyperprolactinemia among atypical antipsychotics due to potent D2 blockade.
- Extrapyramidal symptoms are dose-dependent and occur more with risperidone than most other atypicals.
- Black box warning: increased mortality in elderly patients with dementia-related psychosis.
- Active metabolite 9-hydroxyrisperidone (paliperidone) is formed by CYP2D6 and contributes to therapeutic effect.
- FDA-approved for schizophrenia, bipolar mania, and irritability in autism spectrum disorder.
- Long-acting injectable has a 3-week lag; continue oral risperidone during initiation.
- Monitor metabolic parameters: weight, glucose, lipids, and blood pressure regularly.
- Neuroleptic malignant syndrome is a rare but life-threatening emergency requiring immediate discontinuation.
Indications
Risperidone is FDA-approved for:
- Schizophrenia in adults and adolescents aged 13 years and older
- Bipolar I disorder acute manic or mixed episodes as monotherapy (adults and children 10 years and older) or adjunct to lithium or valproate (adults)
- Irritability associated with autism spectrum disorder in children and adolescents aged 5 to 16 years
Off-label uses include treatment-resistant depression (augmentation), Tourette syndrome, behavioral disturbances in dementia (though this carries a black box warning), obsessive-compulsive disorder augmentation, and acute agitation. It is also used for maintenance therapy in schizophrenia and bipolar disorder to prevent relapse.
Risperidone is available in oral tablets, orally disintegrating tablets, oral solution, and long-acting injectable (risperidone microspheres) for patients requiring improved adherence.
Pharmacokinetics
Risperidone is well absorbed after oral administration with peak plasma concentrations reached in 1 to 2 hours. Bioavailability is approximately 70% and is not significantly affected by food. It is extensively metabolized in the liver by CYP2D6 to the active metabolite 9-hydroxyrisperidone (paliperidone), which has equivalent pharmacological activity.
The pharmacokinetics are affected by CYP2D6 polymorphism: poor metabolizers have higher risperidone levels and lower paliperidone levels, but total active moiety (risperidone plus paliperidone) remains similar. The elimination half-life is approximately 3 hours for risperidone and 24 hours for the active metabolite in extensive metabolizers. In poor metabolizers, risperidone half-life extends to 20 hours.
Both risperidone and 9-hydroxyrisperidone are excreted in urine (70%) and feces (14%). Steady-state concentrations are achieved in 1 day for risperidone and 4 to 5 days for the active metabolite. Dosage adjustment is recommended in patients with severe renal or hepatic impairment. The long-acting injectable formulation releases drug over 4 to 6 weeks with a lag time of approximately 3 weeks before therapeutic levels are reached, requiring oral supplementation during initiation.
Adverse effects
Common adverse effects
- Extrapyramidal symptoms (EPS): dose-dependent parkinsonism, akathisia, dystonia; occurs more frequently than with other atypicals due to potent D2 blockade
- Hyperprolactinemia: most common among atypicals; causes galactorrhea, gynecomastia, menstrual irregularities, sexual dysfunction, and potential long-term bone density loss
- Weight gain and metabolic syndrome: increased appetite, hyperglycemia, dyslipidemia, and diabetes mellitus
- Sedation: due to H1 receptor antagonism, particularly at initiation
- Orthostatic hypotension: from alpha-1 adrenergic blockade, especially during dose titration
- Tachycardia: reflex response to orthostatic hypotension
Serious adverse effects
- Neuroleptic malignant syndrome (NMS): rare but life-threatening; presents with hyperthermia, muscle rigidity, altered mental status, autonomic instability, elevated creatine kinase
- Tardive dyskinesia: risk increases with duration of treatment; presents as involuntary movements of face, tongue, and extremities; may be irreversible
- Cerebrovascular events: increased stroke risk in elderly patients with dementia-related psychosis (black box warning)
- QTc prolongation: dose-related risk of torsades de pointes, especially with concomitant QT-prolonging drugs
- Seizures: lowers seizure threshold
- Hyperglycemia and diabetes: monitor fasting glucose and HbA1c
- Agranulocytosis: rare but serious; monitor for signs of infection
Black box warning
Increased mortality in elderly patients with dementia-related psychosis: antipsychotics increase risk of death, primarily from cardiovascular or infectious causes. Risperidone is not approved for this indication.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to risperidone or paliperidone
Relative contraindications and warnings:
- Dementia-related psychosis in elderly patients: black box warning for increased mortality
- Cardiovascular disease: use with caution due to orthostatic hypotension, tachycardia, and QTc prolongation
- Parkinson disease or Lewy body dementia: severe sensitivity to D2 blockade may worsen motor symptoms
- Seizure disorders: lowers seizure threshold
- Diabetes or risk factors for diabetes: monitor glucose regularly
- Hyperprolactinemia-related conditions: prolactin-dependent tumors (e.g., prolactinoma) may worsen
- Hepatic or renal impairment: dose adjustment required
- Prolonged QT interval or concomitant QT-prolonging medications: increased risk of arrhythmias
- History of neuroleptic malignant syndrome: use with extreme caution
Pregnancy and lactation:
Risperidone is FDA pregnancy category C (animal studies show adverse effects; no adequate human studies). Third-trimester exposure is associated with extrapyramidal symptoms and withdrawal symptoms in neonates. Use only if benefit outweighs risk. Risperidone and 9-hydroxyrisperidone are excreted in breast milk; breastfeeding is generally not recommended during treatment.
Drug interactions
Pharmacokinetic interactions
- CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): increase risperidone levels and decrease 9-hydroxyrisperidone; total active moiety may not change significantly, but monitor for increased side effects
- CYP3A4 inducers (carbamazepine, rifampin, phenytoin, St. John's wort): decrease levels of both risperidone and active metabolite; may require dose increase
- CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): modest increase in risperidone levels
Pharmacodynamic interactions
- CNS depressants (benzodiazepines, opioids, alcohol): additive sedation and respiratory depression
- Antihypertensives: additive orthostatic hypotension from alpha-1 blockade
- Dopamine agonists (levodopa, bromocriptine): antagonistic effects; risperidone may reduce efficacy of dopamine agonists
- QTc-prolonging drugs (class IA and III antiarrhythmics, macrolides, fluoroquinolones, other antipsychotics): increased risk of torsades de pointes
- Other antipsychotics or medications causing EPS: additive extrapyramidal symptoms
- Medications lowering seizure threshold: additive risk of seizures
Alcohol should be avoided due to additive CNS depression and increased risk of orthostatic hypotension.
Clinical pearls
- Risperidone causes more hyperprolactinemia than any other atypical antipsychotic due to its potent D2 blockade in the tuberoinfundibular pathway; check prolactin levels if patients develop galactorrhea, menstrual changes, or sexual dysfunction.
- Unlike most atypicals, risperidone has a dose-dependent risk of EPS; higher doses (above 6 mg/day) approach first-generation antipsychotic EPS rates. Keep doses as low as therapeutically effective.
- When initiating the long-acting injectable, continue oral risperidone for the first 3 weeks because there is a lag before therapeutic levels are reached from the depot formulation.
- Risperidone's active metabolite paliperidone is marketed separately as an antipsychotic (Invega) and is not dependent on CYP2D6 metabolism, making it more predictable in poor metabolizers.
- Monitor weight, glucose, lipids, and blood pressure regularly as part of metabolic monitoring for all patients on risperidone, particularly in the first few months.
- For autism-related irritability, risperidone is one of only two FDA-approved medications (the other is aripiprazole), but behavioral interventions should remain first-line.
- The orally disintegrating tablet does not require water and dissolves on the tongue, which can improve adherence in patients who may cheek medications.
- Taper gradually when discontinuing to avoid withdrawal symptoms (nausea, vomiting, insomnia, agitation) and minimize risk of relapse in schizophrenia or bipolar disorder.
RISE for risperidone adverse effects: Raised prolactin, Increased weight/insulin resistance, Sedation, EPS (extrapyramidal symptoms).
Practice questions
1. A 28-year-old woman with schizophrenia has been taking risperidone 4 mg daily for 6 months. She reports absent menstrual periods for 3 months and bilateral milky nipple discharge. Physical exam reveals no breast masses. Urine pregnancy test is negative. Which of the following is the most likely cause of her symptoms?
2. A 72-year-old man with Alzheimer disease and agitation is started on risperidone by his primary care physician. Three weeks later, his daughter brings him to the emergency department reporting that he has become more confused and had a fall yesterday. Vital signs show temperature 37.8°C (100°F), blood pressure 90/60 mmHg supine and 70/45 mmHg standing, and heart rate 105/min. What is the most appropriate next step in management?
3. A 19-year-old man with schizophrenia treated with risperidone 6 mg daily presents with 2 days of muscle stiffness, fever, confusion, and dark urine. Examination shows temperature 39.5°C (103.1°F), blood pressure 160/95 mmHg, heart rate 120/min, severe generalized rigidity, and diaphoresis. Laboratory studies show creatine kinase 45,000 U/L and creatinine 2.1 mg/dL. Which of the following is the most likely diagnosis?
Frequently asked questions
How does risperidone work?
Risperidone works by blocking dopamine D2 receptors and serotonin 5-HT2A receptors in the brain. The D2 antagonism reduces positive symptoms of psychosis like hallucinations and delusions, while 5-HT2A blockade may improve negative symptoms and partially offset movement side effects. At higher doses, stronger D2 blockade leads to more extrapyramidal symptoms and elevated prolactin levels.
What are the side effects of risperidone?
Common side effects include weight gain, sedation, orthostatic hypotension, elevated prolactin (causing menstrual changes, breast discharge, sexual dysfunction), and extrapyramidal symptoms like stiffness and restlessness. Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, metabolic syndrome with diabetes, QTc prolongation, and increased stroke risk in elderly patients with dementia. Risperidone causes more hyperprolactinemia and dose-dependent movement side effects than most other atypical antipsychotics.
Is risperidone a controlled substance?
No, risperidone is not a controlled substance. It is a prescription antipsychotic medication with no potential for abuse or dependence. However, it requires close monitoring due to serious side effects including metabolic changes, movement disorders, and cardiovascular risks. It should be prescribed and managed by healthcare providers experienced in treating psychiatric conditions.
Risperidone vs olanzapine — what is the difference?
Both are atypical antipsychotics used for schizophrenia and bipolar disorder, but risperidone causes significantly more hyperprolactinemia and extrapyramidal symptoms due to stronger D2 blockade, while olanzapine causes more weight gain, sedation, and metabolic side effects due to greater affinity for histamine and muscarinic receptors. Olanzapine has stronger anticholinergic effects (dry mouth, constipation), whereas risperidone causes more orthostatic hypotension. Choice depends on side effect profile tolerance and individual patient factors.
Can risperidone cause weight gain?
Yes, risperidone causes moderate weight gain, though typically less than olanzapine or clozapine. Weight gain results from histamine H1 receptor blockade, increased appetite, and metabolic changes. It is associated with development of metabolic syndrome, including hyperglycemia, dyslipidemia, and increased risk of type 2 diabetes. Regular monitoring of weight, fasting glucose, and lipids is essential, and lifestyle interventions should be implemented early in treatment.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AX08
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.